Compare AbCellera Biologics Inc (ABCL) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Mondaycom Ltd — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Mondaycom Ltd trades at $81.3 (market cap $3.61B). The key difference: Mondaycom Ltd is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| ABCL | MNDY | |
|---|---|---|
Market Cap | $2.35B | $3.61B |
Sector | Health | Technology |
52-Week High | $8.12 | $309.62 |
52-Week Low | $2.78 | $58.81 |
Enterprise Value | $1.99B | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Monday.com (MNDY) trades at $82.50, up 3.42% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $1.15 vs. $0.96 expected) and impressive 89% gross margins. Recent news highlights institutional interest despite some insider selling, while technical indicators suggest the stock is approaching resistance at $84.
The outlook remains positive with a $116.75 consensus price target (41% upside potential), though risks include high valuation multiples (P/E 36, EV/EBITDA 111) and projected negative cash flow in 2026. Revenue growth stability at 9%+ net margins supports the bullish case, but investors should monitor competitive pressures in the SaaS sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
